Why is this study being conducted?
This study will evaluate the safety, effectiveness and immune response of a messenger RNA (mRNA)–based investigational vaccine aimed at protecting against norovirus disease.
Who is eligible to participate in this study?
You may be eligible if you:
- Are over 18 years of age
- Are in good health or have a well-controlled medical condition
- Do not have a chronic gastrointestinal disease that is associated with ongoing symptoms of vomiting and/or diarrhea
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be up to 2 years and participants will have at least 6 trial visits
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will receive 1 dose of the study vaccine or placebo during the study.
You will have 6 safety phone calls.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Cassandra Balinas
For more information about this clinical trial contact:
Cassandra Balinas, Clinical Trial Coordinator.
07 5678 0362 clinicaltrialunit@griffith.edu.au
This study has been approved by Bellberry Limited #2024-09-1261 and GU HREC #2025/015.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials